Quantinno Capital Management LP Makes New $1.73 Million Investment in Heartflow, Inc. $HTFL

Quantinno Capital Management LP purchased a new stake in Heartflow, Inc. (NASDAQ:HTFL) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 71,271 shares of the company’s stock, valued at approximately $1,734,000.

Other large investors also recently modified their holdings of the company. Sei Investments Co. lifted its position in shares of Heartflow by 342.5% during the 1st quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock valued at $1,631,000 after acquiring an additional 51,895 shares during the period. Seven Grand Managers LLC grew its holdings in Heartflow by 100.0% in the fourth quarter. Seven Grand Managers LLC now owns 100,000 shares of the company’s stock worth $2,915,000 after purchasing an additional 50,000 shares during the period. XXEC Inc. increased its stake in Heartflow by 564.8% in the first quarter. XXEC Inc. now owns 278,681 shares of the company’s stock valued at $6,780,000 after purchasing an additional 236,761 shares in the last quarter. UBS Group AG raised its holdings in shares of Heartflow by 228.8% during the fourth quarter. UBS Group AG now owns 501,165 shares of the company’s stock valued at $14,609,000 after purchasing an additional 348,753 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Heartflow by 8.8% during the fourth quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock valued at $46,066,000 after purchasing an additional 128,400 shares during the period.

Insider Buying and Selling at Heartflow

In other Heartflow news, insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the transaction, the insider directly owned 78,731 shares of the company’s stock, valued at $2,231,236.54. The trade was a 10.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $27.75, for a total transaction of $626,095.50. Following the completion of the sale, the chief executive officer owned 435,373 shares of the company’s stock, valued at approximately $12,081,600.75. This represents a 4.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,243 shares of company stock valued at $2,891,879 in the last quarter. 7.70% of the stock is currently owned by corporate insiders.

Heartflow Stock Performance

HTFL stock opened at $29.54 on Wednesday. The business has a 50-day simple moving average of $28.74 and a two-hundred day simple moving average of $27.73. The company has a market capitalization of $2.55 billion and a P/E ratio of -9.50. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $41.22.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. Heartflow’s quarterly revenue was up 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on HTFL. Canaccord Genuity Group reduced their target price on Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Robert W. Baird initiated coverage on Heartflow in a report on Friday, July 31st. They issued an “outperform” rating and a $34.00 price target on the stock. Wells Fargo & Company raised their price objective on Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. William Blair began coverage on Heartflow in a report on Monday, May 4th. They set an “outperform” rating for the company. Finally, Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Heartflow has an average rating of “Moderate Buy” and a consensus price target of $36.57.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.